Ainos, Inc.: directors' dealings · United States · SEC (Form 4)

About Ainos, Inc.

Ainos, Inc. is a U.S.-based healthcare and medtech company listed on NASDAQ in the United States under the symbols AIMD and AIMDW. For French, Belgian, and Swiss investors, it is best viewed as a small-cap R&D-driven name at the intersection of biotechnology, diagnostics, and applied artificial intelligence. The company traces its roots back to 1984, when it was founded around low-dose interferon alpha research. Over time, Ainos expanded and has more recently repositioned itself as a diversified medtech platform centered on three business pillars: low-dose interferon therapeutics, point-of-care diagnostic devices, and its proprietary AI Nose platform, which is designed to convert odor signals into machine-readable data for AI applications. ([ainos.com](https://www.ainos.com/?utm_source=openai)) Ainos’ U.S. operating headquarters is now in Houston, Texas, following an announced relocation from San Diego. The company also maintains a Taiwan presence, reflecting a bi-regional operating model that combines clinical development, intellectual property generation, and industrial partnerships. Ainos says it holds more than 60 patents in total, including over 50 digital nose-related patents, which is central to its differentiation in a niche and still early-stage technology category. ([ainos.com](https://ainos.com/news_view/89?utm_source=openai)) From a product standpoint, Ainos is developing and/or commercializing several product families: VELDONA, its low-dose oral interferon program; AI Nose, its scent-intelligence platform; and diagnostic applications such as Ainos Flora, Ainos Pen, antigen test kits, and other point-of-care tools. The company’s competitive position is that of a specialized innovator rather than a scaled commercial healthcare platform. Its strategy is aimed at markets with potentially large addressable opportunities but relatively low current penetration, including hygiene monitoring, industrial environments, connected healthcare, and selected clinical-use cases. ([ainos.com](https://www.ainos.com/?utm_source=openai)) Recent corporate developments have been centered on the commercialization push for AI Nose. In 2025, Ainos launched its first commercial AI Nose module and announced pilot and partnership activity in Japan and with ASE Technology Holding, including a reported ambition to deploy up to 15,000 units across selected sites. In May 2026, the company said execution on AI Nose was advancing in semiconductor and healthcare infrastructure settings, indicating movement from validation toward broader deployment readiness. For investors, Ainos remains a highly speculative transformation story, dependent on execution, future financing, and the ability to convert intellectual property into recurring revenue streams. ([ainos.com](https://ainos.com/news_view/78?utm_source=openai))